Nurix Entered into a Multi-Year, Multi-Target Strategic Collaboration Agreement with Seagen to Advance an Innovative New Class of Cancer Therapies
- Nurix will receive $60M up front & is eligible to receive ~$3.4B in research, development, regulatory & commercial milestones across multiple programs along with royalties on future sales
- Nurix holds an option for US profit sharing & co-promotion on 2 products. Both companies combine their technologies, ADC and TPD to develop therapies with new mechanisms of action as well as improved specificity & anti-cancer activity
- Nurix will develop a suite of targeted protein degraders against multiple targets nominated by Seagen that are suitable for Ab conjugation using its DELigase platform. Seagen will be responsible for conjugating these degraders to Abs to make DACs (Degrader-Antibody Conjugates) for cancer and advance these through preclinical, clinical development & commercialization
Ref: Globenewswire | Image: Seagen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.